295 related articles for article (PubMed ID: 20954856)
21. Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine.
Lee KR; Kim EJ; Seo SW; Choi HK
Arch Pharm Res; 2008 Aug; 31(8):1023-8. PubMed ID: 18787792
[TBL] [Abstract][Full Text] [Related]
22. The impact of the injection mold temperature upon polymer crystallization and resulting drug release from immediate and sustained release tablets.
Van Renterghem J; Dhondt H; Verstraete G; De Bruyne M; Vervaet C; De Beer T
Int J Pharm; 2018 Apr; 541(1-2):108-116. PubMed ID: 29409747
[TBL] [Abstract][Full Text] [Related]
23. Effects of Dissolution Medium pH and Simulated Gastrointestinal Contraction on Drug Release From Nifedipine Extended-Release Tablets.
Gao Z; Ngo C; Ye W; Rodriguez JD; Keire D; Sun D; Wen H; Jiang W
J Pharm Sci; 2019 Mar; 108(3):1189-1194. PubMed ID: 30343136
[TBL] [Abstract][Full Text] [Related]
24. Comparison of dissolution profiles obtained from nifedipine extended release once a day products using different dissolution test apparatuses.
Garbacz G; Golke B; Wedemeyer RS; Axell M; Söderlind E; Abrahamsson B; Weitschies W
Eur J Pharm Sci; 2009 Sep; 38(2):147-55. PubMed ID: 19591927
[TBL] [Abstract][Full Text] [Related]
25. Soluble filler as a dissolution profile modulator for slightly soluble drugs in matrix tablets.
Dvorácková K; Rabisková M; Masteiková R; Muselík J; Krejcová K
Drug Dev Ind Pharm; 2009 Aug; 35(8):930-40. PubMed ID: 19274510
[TBL] [Abstract][Full Text] [Related]
26. Development of tablets for controlled joint release of nifedipine and atenolol.
Iglesias R; Taboada C; Souto C; Martínez-Pacheco R; Gómez-Amoza JL; Concheiro A
Drug Dev Ind Pharm; 1998 Sep; 24(9):835-40. PubMed ID: 9876534
[TBL] [Abstract][Full Text] [Related]
27. Optimization of matrix tablets controlled drug release using Elman dynamic neural networks and decision trees.
Petrović J; Ibrić S; Betz G; Đurić Z
Int J Pharm; 2012 May; 428(1-2):57-67. PubMed ID: 22402474
[TBL] [Abstract][Full Text] [Related]
28. Optimization and characterization of a pH-independent extended-release hydrophilic matrix tablet.
Timmins P; Delargy AM; Howard JR
Pharm Dev Technol; 1997 Feb; 2(1):25-31. PubMed ID: 9552428
[TBL] [Abstract][Full Text] [Related]
29. Formulation study and drug release mechanism of a new theophylline sustained-release preparation.
Hayashi T; Kanbe H; Okada M; Suzuki M; Ikeda Y; Onuki Y; Kaneko T; Sonobe T
Int J Pharm; 2005 Nov; 304(1-2):91-101. PubMed ID: 16154302
[TBL] [Abstract][Full Text] [Related]
30. Citric acid monohydrate as a release-modifying agent in melt extruded matrix tablets.
Schilling SU; Bruce CD; Shah NH; Malick AW; McGinity JW
Int J Pharm; 2008 Sep; 361(1-2):158-68. PubMed ID: 18582547
[TBL] [Abstract][Full Text] [Related]
31. Formulation development and in vitro evaluation of theophylline microcapsules.
Ahmad M; Akhtar N; Murtaza G; Hussain SW
Pak J Pharm Sci; 2012 Jan; 25(1):15-9. PubMed ID: 22186304
[TBL] [Abstract][Full Text] [Related]
32. Modified drug release of poloxamer matrix by including water-soluble and water-insoluble polymer.
Gonzalez YM; Ghaly ES
Drug Dev Ind Pharm; 2010 Jan; 36(1):64-71. PubMed ID: 19747067
[TBL] [Abstract][Full Text] [Related]
33. Use of xanthan and its binary blends with synthetic polymers to design controlled release formulations of buccoadhesive nystatin tablets.
Sakeer K; Al-Zein H; Hassan I; Martin GP; Nokhodchi A
Pharm Dev Technol; 2010; 15(4):360-8. PubMed ID: 19772376
[TBL] [Abstract][Full Text] [Related]
34. Formulation and characterization of modified release tablets containing isoniazid using swellable polymers.
Akhtar MF; Rabbani M; Sharif A; Akhtar B; Saleem A; Murtaza G
Afr J Tradit Complement Altern Med; 2011; 8(3):250-9. PubMed ID: 22468003
[TBL] [Abstract][Full Text] [Related]
35. Controlled release of nifedipine from gelatin microspheres and microcapsules: in vitro kinetics and pharmacokinetics in man.
Leucuţa SE
J Microencapsul; 1990; 7(2):209-17. PubMed ID: 2329447
[TBL] [Abstract][Full Text] [Related]
36. Sustained release phenylpropanolamine hydrochloride from ATO 888 matrix.
Perez MA; Ghaly ES; Marti A
P R Health Sci J; 1993 Dec; 12(4):263-7. PubMed ID: 8140204
[TBL] [Abstract][Full Text] [Related]
37. Kinetic release of theophylline from hydrophilic swellable matrices.
Vargas CI; Ghaly ES
Drug Dev Ind Pharm; 1999 Sep; 25(9):1045-50. PubMed ID: 10518245
[TBL] [Abstract][Full Text] [Related]
38. Drug release behaviour from methyl methacrylate-starch matrix tablets: effect of polymer moisture content.
Bravo-Osuna I; Ferrero C; Jiménez-Castellanos MR
Eur J Pharm Biopharm; 2008 May; 69(1):285-93. PubMed ID: 17997292
[TBL] [Abstract][Full Text] [Related]
39. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets.
Ceballos A; Cirri M; Maestrelli F; Corti G; Mura P
Farmaco; 2005; 60(11-12):913-8. PubMed ID: 16129436
[TBL] [Abstract][Full Text] [Related]
40. Nifedipine solid dispersion in microparticles of ammonio methacrylate copolymer and ethylcellulose binary blend for controlled drug delivery. Effect of drug loading on release kinetics.
Huang J; Wigent RJ; Bentzley CM; Schwartz JB
Int J Pharm; 2006 Aug; 319(1-2):44-54. PubMed ID: 16678366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
